Neurodegenerative Disorder

In Tuesday’s pre-market trading, ANEW Medical, Inc. (NASDAQ:WENA) saw its shares surge nearly 80% following an announcement about the advancement of its patented Klotho gene therapy program for neurodegenerative disorders. What Happened: ANEW, a biopharmaceutical company that specializes in...

FSD Pharma Inc. (NASDAQ: HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targetting multiple sclerosis. The biopharma company is currently developing three drug candidates through its wholly-owned...

Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The drug failed the primary endpoint on significantly improving...

FSD Pharma Inc (NASDAQ: HUGE) shares rebounded after falling in premarket on acquiring a Canada-based psychedelic pharmaceutical company. Related: See Why FSD Pharma Terminated COVID-19 Trial FSD Pharma has agreed to acquire Lucid Psycheceuticals Inc for approximately $9...

Ipsen SA (OTC: IPSEY) and Exicure Inc (NASDAQ: XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington's disease and Angelman syndrome. Oligonucleotides are synthetic...

Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders. Data were presented at the American Academy of Neurology virtual annual...